QSI, QSIAW · CIK 0001816431 · operating
Quantum-Si develops and commercializes a single-molecule detection platform for Next Generation Protein Sequencing (NGPS). The company's core offering enables protein analysis at the amino acid level, addressing applications including antibody characterization, biomarker identification, protein variants, and post-translational modification analysis. The platform serves researchers across pharmaceutical, biotechnology, and academic laboratory settings.
The company's product portfolio consists of the Platinum and Platinum Pro NGPS instruments, which provide single-molecule amino acid resolution with automated data analysis capabilities. Supporting this hardware are library preparation kits, barcoding kits, sequencing kits, and Platinum Analysis Software, a cloud-based data analysis solution. Revenue is generated through instrument sales and recurring consumables purchases.
Quantum-Si operates with approximately 149 full-time employees and maintains headquarters in Branford, Connecticut. The company is incorporated in Delaware and trades on the Nasdaq. Founded in 2013, it operates within the medical devices sector, specifically in measuring and controlling devices.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.71 | $-0.71 | -4.4% | |
| 2023 | $-0.68 | $-0.68 | +28.4% | |
| 2022 | $-0.95 | $-0.95 | +20.2% | |
| 2021 | $-1.19 | $-1.19 | — | |
| 2020 | — | — | — |